Home / Health / NY Fights 'Smuggled' Cadaver Fat for Breast Enhancement
NY Fights 'Smuggled' Cadaver Fat for Breast Enhancement
9 Sep
Summary
- New York is fighting Tiger Aesthetics over distributing cadaver fat for cosmetic use.
- The company allegedly 'smuggled' the product into New York from New Jersey.
- A patient experienced lumps and masses after receiving alloClae injections.
A significant dispute has arisen in New York concerning the regulation of human tissue for cosmetic procedures, specifically involving a product called alloClae, a type of cadaver fat marketed for breast enhancement.
Tiger Aesthetics sought a New York license to distribute alloClae, but the state denied the request, citing unclear compliance with FDA requirements. Investigations revealed over 330 boxes of alloClae were shipped to a nurse's residence in Tinton Falls, New Jersey, between 2025 and 2026. State regulators allege this material was then transported into New York City, describing the activity as "smuggling" and raising serious safety concerns.
Tiger Aesthetics is challenging New York's licensing requirements, arguing that product approvals fall under federal jurisdiction. The company states that the FDA has inspected their facilities multiple times and found them to be compliant. However, New York has revoked other provisional licenses for Tiger, citing a lack of "character and competence," partly due to a past incident where company representatives allegedly misrepresented storage and shipping practices at a Pennsylvania facility.
Meanwhile, a patient who received alloClae injections reported developing lumps and masses in her breasts, diagnosed as consistent with "evolving fat necrosis." While Tiger claims such complications are rare and technique-dependent, the patient's medical records detail significant nodule formation. Medical professionals express caution regarding the use of cadaver fat in breast procedures due to the inherent risks and monitoring required for this sensitive area.
